ZNTL News
Archived Headlines
- US IPO Week Ahead: Another biotech plans to take on the IPO market 04/03/20
- US IPO Weekly Recap: Zentalis Pharma defies sell-off as biotech pops 29% 04/03/20
- Zentalis Pharmaceuticals prices upsized IPO at $18, the high end of the range 04/02/20
- Oncology biotech Zentalis Pharmaceuticals sets terms for $130 million IPO scheduled for this week 03/30/20
- US IPO Week Ahead: A biotech and a Chinese hologram company take on a tough IPO market 03/27/20
See more
Renaissance Capital's 2Q 2020 US IPO Market Review
The IPO Market Stages a Swift Recovery The second quarter saw ...read more
2020 biotech IPOs now average an 80% return from their offer price
The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more
The IPO market’s slowest spring since the financial crisis
The 2020 IPO market saw its slowest March and April in over a decade, as volatility essentially shut the IPO window. Just seven IPOs priced during the past two months, a 70% decline from the 15-year average of 23 IPOs. ...read more
US IPO Week Ahead: An empty calendar and a quiet week for the IPO market
There are no IPOs scheduled for the week ahead. The most likely April IPOs Despite the encouraging market rally this past week, the Renaissance IPO Volatility Index is still about double the five-year average and few companies have filed,...read more